Loading stock data…
Myriad Genetics, Inc. (MYGN)
$3.18-0.01 (-0.31%)
Market ClosedLast close Sep 8
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Myriad Genetics, Inc. in the Healthcare sector is trading at $3.18 with a market capitalization of $290M. Wall Street consensus targets $3.34 (8 analysts), implying a +5.0% move over the next 12 months. The stock is currently near its 52-week low of $2.74, remaining 37.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $190.70M↓ | $200.40M↓ | $209.80M↑ | $205.70M↓ | $213.10M |
| Gross Profit | $127.00M↓ | $137.60M↓ | $146.80M↑ | $143.80M↓ | $151.80M |
| Operating Income | -$38.90M↓ | -$25.30M↓ | -$3.00M↑ | -$23.30M↓ | -$12.50M |
| Net Income | -$43.20M↓ | -$34.10M↓ | -$7.90M↑ | -$27.40M↑ | -$330.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$289.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.05%
Volume
Today's trading volume
1.19M
Recent News
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers.
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Piper Sandler (PIPR) Stock May Be Fully Valued After A Fresh Downgrade Call
Piper Sandler Companies stock has delivered a strong 158.7% gain over the past five years, yet current valuation checks point to a stock that screens as comparatively expensive rather than a clear bargain. Recent share price softness, including a decline of 14.1% year to date, adds an extra layer of scrutiny to what investors are paying for the business today. Piper Sandler Companies has returned 158.7% over five years, which raises the question of how much of that success is already...
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter
Check out the companies making headlines yesterday: